23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

23andMe will reportedly pay $30 million to settle a lawsuit tied to a data breach. As Reuters reported Friday (Sept.

23andMe Reportedly Paying $30 Million to Settle Data Breach Suit

23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, offering potential indications to assess clinical activity Phase 1 trial ongoing with first patient dosed in March 2024 SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced nonclinical data supporting the anti-tumor activity of its first-in-class 23ME-01473 ('1473) antibody targeting the NKG2D ligand ULBP6 at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, September 13-17.

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23andMe will pay $30 million and provide three years of security monitoring to settle a lawsuit accusing the genetics testing company of failing to protect the privacy of 6.9 million customers whose personal information was exposed in a data breach last year.

23andMe settles data breach lawsuit for $30 million

23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population 23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population

One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations

23andMe co-founder and chief executive Anne Wojcicki would be open to considering third-party takeover proposals for the company, a regulatory filing showed on Wednesday.

23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows

Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented

23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024

In conjunction with this new offering, 23andMe, Lemonaid Health's parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s In conjunction with this new offering, 23andMe, Lemonaid Health's parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s

Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data

NEW YORK, NY / ACCESSWIRE / August 13, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

23andMe Holding Co. (NASDAQ:ME ) Q1 2025 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ian Cooney - Senior Director, Investor Relations Joe Selsavage - Chief Financial Officer and Chief Accounting Officer Anne Wojcicki - Chief Executive Officer and Co-Founder Jennifer Low - Head, Therapeutics Development Conference Call Participants Operator Hello, and welcome to 23andMe's Fiscal Year 2025 First Quarter Financial Results Conference Call. As a reminder this call is being recorded.

23andMe Holding Co. (ME) Q1 2025 Earnings Call Transcript

NEW YORK, NY / ACCESSWIRE / August 9, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2025 (FY25), which ended June 30, 2024.

23andMe Reports First Quarter Fiscal 2025 Financial Results

Dublin, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The "Direct-to-Consumer (DTC) Genetic Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Direct-to-Consumer (DTC) Genetic Testing is estimated at US$1.3 Billion in 2023 and is projected to reach US$3.4 Billion by 2030, growing at a CAGR of 14.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Direct-to-Consumer (DTC) Genetic Testing Business Report 2023-2030 with Focus on 80+ Players Including 23andMe, Ancestry.com, Chengdu 23Mofang Biotechnology, and DirectLabs

Genetic testing firm 23andMe will not go ahead with CEO Anne Wojcicki's take-private offer and has asked her to withdraw any plan to oppose an alternative deal, the company said on Friday.

23andMe rejects CEO Anne Wojcicki's take-private offer

23andMe (NASDAQ: ME ) stock is in the news Friday as investors react to the company's co-founder offering to take it private in a $200 million deal. According to a 23andMe press release, chairman and CEO Anne Wojcicki is willing to pay 40 cents per share for ME stock to take the company private.

ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe

23andMe said on Friday that it will not go ahead with CEO Anne Wojcicki's take-private offer and has asked her to withdraw any plan to oppose any alternative deal.

23andMe rejects CEO Wojcicki take-private offer

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in response to Ms. Wojcicki's previously disclosed preliminary non-binding indication of interest to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per share of Class A Common Stock or Class B Common Stock:

23andMe Special Committee responds to CEO's take-private proposal

23andMe co-founder and chief executive Anne Wojcicki made a non-binding proposal to the board to acquire all of the company's outstanding shares not already owned by her or her affiliates for $0.40 per share, a filing showed on Wednesday.

23andMe CEO Wojcicki makes offer to take the firm private, filing shows

23andMe CEO Anne Wojcicki has submitted a proposal to take the genetic testing company private. She is prepared to acquire all of 23andMe's outstanding shares of common stock in cash for 40 cents per share, according to a filing with the SEC Wednesday.

23andMe CEO files proposal to take company private as stock craters

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress.

23andMe to Report Q1 FY2025 Financial Results

Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Avalo Therapeutics

Veracyte

It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more targeted and therefore better advice on their diet.

The 3 Best Personalized Nutrition Stocks to Buy Now

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the potential take-private transaction of 23andMe Holding Co. (NasdaqCM: ME) (the “Company”). If you would like to discuss your legal rights regarding the potential transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768.

News for 23andMe Stock (ME)